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PakistanAbstract Griscelli syndrome type 2 is a rare autosomal recessive disease caused by mutations in the
RAB27A gene. It is characterized by pigmentary dilution of the skin and hair causing silvery gray
hair, hemophagocytic lymphohistiocytosis and characteristic light microscopy findings in scalp hair
shaft seen as large irregular clumps of pigment as opposed to the evenly distributed pigment along
the hair shaft without any clumps. We describe a boy with classic features of Griscelli syndrome
type 2 from Pakistan in whom a homozygous mutation in the RAB27A gene was identified that
showed a single base substitution (c.598C>T) predicted to cause premature protein termination
(p.Arg200*). We also present a clinical approach to silver blonde hair differentiating between the
Griscelli syndrome types 1, 2 and 3, Chediak Hegashi Syndrome and Elejalde Syndrome.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Griscelli syndrome (GS) is a rare autosomal recessive disorder
that was first described by Griscelli et al. in 1978 [1]. Silvery
hair and hypopigmentation along with varying degrees of
immunologic and neurologic dysfunction are the prominent
clinical features of GS. Three subtypes, GS-1-3, share similar
pigmentary dilution of the skin and hair causing silvery gray
hair [2]. Mutations in theMYO5A gene causing GS-1 (OMIM
# 214450) are clinically similar to Neuroectodermal
melanolysosomal disease (Elejalde Syndrome OMIM #256710) [3]. Both are characterized by neurological impairment
without immunological impairment. GS-2 (OMIM # 607624)
is caused by mutations in the RAB27A gene and is character-
ized by severe immunological impairment without primary
neurological impairment [4]. The neurological deficit that
occurs in GS-2 seems to be secondary to the infiltration and
proliferation of leukocytes in the brain [5]. GS-3 (OMIM #
609227) is caused by a defect in the MLPH gene and presents
with only partial albinism and silvery hair without the neuro-
logic and immunologic involvement [2]. Prognosis of GS
depends on the subtypes. There is no treatment for GS-1 and
quality of life depends on the severity of neurological impair-
ment. GS-3 does not require treatment. Patients with GS-2
succumb to illness due to the accelerated hemophagocytic syn-
drome phase secondary to immunological impairment unless
an early bone marrow transplant (BMT) is performed [6].
Therefore, early recognition of GS-2 is critical.
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worldwide [7] including one GS case from Pakistan, which
was diagnosed clinically without molecular characterization
of the subtype [8]. We present the first case of GS-2 from
Pakistan in whom a homozygous non-sense mutation in the
RAB27A gene was confirmed.
2. Case report
A 4 month old boy born to healthy first-cousin, once removed
parents after an uneventful full term pregnancy was referred to
a genetic clinic for the evaluation of hepatosplenomegaly noted
from 3 months of age. At birth his weight was 3.3 kg, length
was 52 cm and head circumference was 35.4 cm. As compared
to the healthy family members, he was noted to have very fairSilvery g
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Figure 1 Approach to patienskin, silvery blonde scalp hair, eyebrows and eye lashes. His
early developmental miles stones were achieved at appropriate
ages. Parents were concerned for his partial albinism in view of
the two other children who died at 40 days of life with pneu-
monia and 6 years of age with sepsis and who also had hep-
atosplenomegaly. Both the deceased sibs had similar fair skin
and silver blonde scalp hair as the proband. None of the other
healthy sibs had similar skin hypopigmentation or silvery
blonde hair. Parents reported a history of recurrent fever in
the patient described in this paper, which were often treated
with oral antibiotics. However, he was never admitted with a
serious infection nor his blood cultures grew any pathogenic
micro-organism. On further interviewing, parents described
their deceased six-year old as an intelligent boy who had no
neurological impairment. They further informed that withray hair 
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Figure 2 (a) Silver blonde scalp hair and eye brows and bronze tan skin. (b) Light microscopy of scalp hair shaft showing large irregular
clumps of pigments.
Griscelli syndrome type 2 231age his fair complexion changed to bronze tanning especially in
the sun exposed areas (see Fig. 1).
The physical examination of the proband revealed hep-
atosplenomegaly, however no lymphadenopathy was noted.
The child had good eye contact, with good neck control and
was socially interactive. His growth anthropometry including
weight, height and occipital frontal head circumference were
normal for age.
Investigations showed hemoglobin 7.4 g/dL, total leukocyte
count: 2300/mm3 with absolute neutrophil count of 800, plate-
let count of 85,000/mm3. The peripheral blood smear showed
normocytic and normochromic red blood cells. In view of
the silver gray hair (Fig. 2a), hepatosplenomegaly and spared
neurological manifestation differential diagnosis of Chediak
Hegashi Syndrome and GS-2 was considered. Light micro-
scopy of scalp hair shaft was performed, which showed large
irregular clumps of pigment suggesting GS-2 (Fig. 2b). In the
laboratory evidence of hemophagocytosis; hyper-
triglyceridemia of 352 mg/dL (normal < 150 mg/dL),
hypofibrinogenmia of 104 mg/dL (normal: 150–450) and
hyperferritinemia of 1534 ng/ml (normal: 50–200) were noted.
Bone marrow aspirates for the hemophagocytosis were not
done. For the assessment of humoral immunodeficiency serum
IgG, IgA and IgM were done, which were noted to be low for
his age. Flow cytometry for the assessment of the cellular
immune deficiency was not done due to cost constraints. For
the confirmation of the diagnosis of GS-2; RAB27A2 gene
sequencing was performed at Prevention Genetics in
Marshfield, Wisconsin, U.S.A., which showed a homozygous
single base pair substitution c.598C>T, which is predicted to
causing premature protein termination (p.Arg200*).
At the time of writing this manuscript, preparation for allo-
genic BMT is in process and a HLA matched sibling has been
identified.
3. Discussion
The hemophagocytic syndrome seen in GS-1 and GS-2 is also
described as the accelerated phase. This is secondary to the
uncontrollable T lymphocyte and macrophage hyperactiva-
tion. The main differentiation between GS-1 and GS-2 is the
primary or secondary central nervous system (CNS) involve-ment. The secondary CNS involvement in GS-2 is caused by
the infiltration of lymphocytes and histiocytes as a result of
hemophagocytic syndrome. Temporary remission of the accel-
erated phase seen in GS-2 can be achieved with chemotherapy
or immunotherapy [9]. However, recurrent relapses of increas-
ing severity are frequently observed as infiltration of the CNS
despite maintenance therapy. BMT is the only curative treat-
ment of GS-2. Patients usually succumb to severe infection
or CNS infiltration at an average age of 5 years without
BMT [10]. Thus, prompt diagnosis is vital in the prognosis
of GS-2.
We present the first report describing a case of molecularly
confirmed GS-2 from Pakistan. In our patient, scalp hair
microscopy was suggestive of GS. The hair microscopy finding
together with the clinical and laboratory evidence of
hemophagocytic syndrome without CNS involvement
prompted us to the diagnosis of GS-2.
The homozygous c.598C>T mutation in RAB27A gene,
predicted to cause premature protein termination (p.arg200*)
confirmed the diagnosis of GS-2 in our patient. The same
mutation in the RAB27A gene has been reported in a patient
in whom hydrocephalus and multiple contrast enhancing
lesions in the cerebellar, cerebral cortex, and spinal cord were
described. However, these lesions showed lymphocyte and his-
tiocyte infiltration with evidence of hemophagocytic lympho-
histiocytosis [11].
Differentiation between GS-1 and GS-2 is essential because
BMT is the definitive treatment for GS-2 but has no role in
GS-1 caused by MYO5A. At the time of writing of this
manuscript arrangements for an allogenic BMT from a
HLA-matched sibling are underway.Conflict of interest
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